Female sexual dysfunction: a focus on flibanserin
Nicole M Lodise Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA Abstract: Flibanserin is the first US Food and Drug Administration (FDA)-approved option for sexual dysfunction, specifically low sexual desire. Until recently, there were no FDA-approved...
Saved in:
Main Author: | Lodise NM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin
by: Jayne CJ, et al.
Published: (2017) -
Drug flibanserin-in hypoactive sexual desire disorder
by: Pugazhenthan Thangaraju, et al.
Published: (2022) -
Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study
by: Marianne J. Naguib, et al.
Published: (2021) -
FEMALE SEXUAL DYSFUNCTION
by: C. DADAK, et al.
Published: (2016) -
Preparation, characterization, dissolution, and permeation of flibanserin − 2-HP-β-cyclodextrin inclusion complexes
by: Adel F. Alghaith, et al.
Published: (2021)